GlaxoSmithKline to seek EMA approval for 2015 malaria vaccine launch

GlaxoSmithKline's ($GSK) experimental malaria vaccine may not have delivered results as strong as the company hoped. But it does offer enough protection to slash the number of cases in infants for a time, a new study shows, and so Glaxo plans to ask European regulators for approval. The vaccine could be shipped by 2015. Report

Suggested Articles

Creating a relevant online health user experience has its payoffs — for both the user and the brand. Here’s why.

Sanofi's new strategy delivered for the drugmaker in the third quarter as Dupixent posted blockbuster sales and flu vaccines set a revenue record.

Catalent has acquired Bone Therapeutics' cell and gene therapy site in Gosselies, Belgium, to add to its growing "center of excellence" there.